OSR Holdings Inc (OSRH)
OSR Holdings Inc. is a NASDAQ-listed healthcare company focused on biotechnology and related healthcare solutions. Through its operations in the United States, Switzerland, and South Korea, the company is developing a portfolio of immunotherapy and design-augmented biologic programs. Its pipeline includes VXM01, an immuno-oncology candidate for glioblastoma that is in phase 2 clinical testing, along with earlier-stage programs such as VXM04 for mesothelin, VXM06 for Wilms Tumor Protein (WT1), VXM08 for carcinoembryonic antigen (CEA), and VXM10 for PD-L1. OSR Holdings is also advancing DRT-102, a clinical-stage asset for spinal fusion, and DRT-101, a preclinical program for osteoarthritis. In addition, the company distributes neurovascular intervention medical devices and systems. OSR Holdings is based in Bellevue, Washington.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-OSRH
|
$0.55
|
21.4% Upside
|
Undervalued
|
$10 2,122.2% Upside
|
—
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-1.6x
|
0.1x
|
5.9x
|
16.247 M
|
42.364 M
|
11.1%
|
41.7%
|
-38.3
|
—
|
57.0%
|
